Endocrine Switch Plus Ribociclib Active in Post-CDK4/6 Inhibitor Progression
(MedPage Today) -- CHICAGO -- Progression-free survival (PFS) in advanced hormone receptor (HR)-positive/HER2-negative breast cancer improved significantly in patients who received ribociclib (Kisqali) and a different endocrine therapy after...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hematology | HER2 | Hormones